REFERENCES
1. Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 1976;26:1054-9.
4. Engel AG. Disturbances in neuromuscular transmission. In: Engel AG, Franzini-Armstrong C, editors. Myology. 2nd ed. New York: McGraw-Hill; 1994. pp. 1769-97.
5. Onodera H. The role of the thymus in the pathogenesis of myasthenia gravis. Tohoku J Exp Med 2005;207:87-98.
6. Scheife RT, Hills JR, Munsat TL. Myasthenia gravis: signs, symptoms, diagnosis, immunology, and current therapy. Pharmacotherapy 1981;1:39-54.
7. Bedlack RS, Sanders DB. Steroid treatment for myasthenia gravis: steroids have an important role. Muscle Nerve 2002;25:117-21.
8. Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology 1998;50:1778-83.
9. Tindall RS, Phillips JT, Rollins JA, Wells L, Hall K. A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann N Y Acad Sci 1993;681:539-51.
10. Chaudhry V, Cornblath DR, Griffin JW, O'Brien R, Drachman DB. Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology 2001;56:94-6.
11. Drachman DB, Jones RJ, Brodsky RA. Treatment of refractory myasthenia: "rebooting" with high-dose cyclophosphamide. Ann Neurol 2003;53:29-34.
12. Ponseti JM, Azem J, Fort JM, Codina A, Montoro JB, Armengol M. Benefits of FK506 (tacrolimus) for residual, cyclosporin- and prednisone-resistant myasthenia gravis: one-year follow-up of an open-label study. Clin Neurol Neurosurg 2005;107:187-90.
13. Pescovitz MD. Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am J Transplant 2006;6:859-66.
14. Chiu HC, Chen WH, Yeh JH. The six year experience of plasmapheresis in patients with myasthenia gravis. Ther Apher 2000;4:291-5.
15. Wegner B, Ahmed I. Intravenous immunoglobulin monotherapy in long-term treatment of myasthenia gravis. Clin Neurol Neurosurg 2002;105:3-8.
16. Gronseth GS, Barohn RJ. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the quality standards subcommittee of the American academy of neurology. Neurology 2000;55:7-15.
17. Tucker DM, Roeltgen DP, Wann PD, Wertheimer RI. Memory dysfunction in myasthenia gravis: evidence for central cholinergic effects. Neurology 1988;38:1173-7.
19. Iwasaki Y, Kinoshita M, Ikeda K, Takamiya K, Shiojima T. Cognitive dysfunction in myasthenia gravis. Int J Neurosci 1990;54:29-33.
20. Glennerster A, Palace J, Warburton D, Oxbury S, Newsom-Davis J. Memory in myasthenia gravis: neuropsychological tests of central cholinergic function before and after effective immunologic treatment. Neurology 1996;46:1138-42.
21. Paul RH, Cohen RA, Gilchrist JM, Aloia MS, Goldstein JM. Cognitive dysfunction in individuals with myasthenia gravis. J Neurol Sci 2000;179:59-64.
22. Hokkanen E, Toivakka E. Electroencephalographic findings in myasthenia gravis 180 EEG recordings of 109 patients. Acta Neurol Scand 1969;45:556-67.
23. Tartara A, Mola M, Manni R, Moglia A, Lombardi M, Poloni M, Piccolo G. EEG findings in 118 cases of myasthenia gravis. Rev Electroencephalogr Neurophysiol Clin 1982;12:275-9.
24. Kazis A, Pappa P, Xafenias D. EEG finding in myasthenia gravis. Electromyogr Clin Neurophysiol 1984;24:577-82.
25. Feldmann R, Kiefer R, Wiegard U, Evers S, Weglage J. Intelligence, attention, and memory in patients with myasthenia gravis. Nervenarzt 2005;76:960, 962-6.
26. Marra C, Marsili F, Quaranta D, Evoli A. Determinants of cognitive impairment in elderly myasthenia gravis patients. Muscle Nerve 2009;40:952-9.
27. Sitek EJ, Bilinska MM, Wieczorek D, Nyka WM. Neuropsychological assessment in myasthenia gravis. Neurol Sci 2009;30:9-14.
28. Vernino S, Cheshire WP, Lennon VA. Myasthenia gravis with autoimmune autonomic neuropathy. Auton Neurosci 2001;88:187-92.
29. Gotkine M, Fellig Y, Abramsky O. Occurrence of CNS demyelinating disease in patients with myasthenia gravis. Neurology 2006;67:881-3.
30. Hamed SA. Comorbid nervous system manifestations and disorders with myasthenia gravis: evidences and possible mechanisms. J Neurol Neurosci 2012;3:2.
31. Stepansky R, Weber G, Zeitlhofer J. Sleep apnea in myasthenia gravis. Wien Med Wochenschr 1996;146:209-10.
32. Amino A, Shiozawa Z, Nagasaka T, Shindo K, Ohashi K, Tsunoda S, Shintani S. Sleep apnoea in well-controlled myasthenia gravis and the effect of thymectomy. J Neurol 1998;245:77-80.
33. Nicolle MW, Rask S, Koopman WJ, George CF, Adams J, Wiebe S. Sleep apnea in patients with myasthenia gravis. Neurology 2006;67:140-2.
34. Lewis SW, Ron MA, Newsom-Davis J. Absence of central functional cholinergic deficits in myasthenia gravis. J Neurol Neurosurg Psychiatry 1989;52:258-61.
35. Paul RH, Cohen RA, Zawacki T, Gilchrist JM, Aloia MS. What have we learned about cognition in myasthenia gravis?: a review of methods and results. Neurosci Biobehav Rev 2001;25:75-81.
36. Paul RH, Cohen RA, Gilchrist JM. Ratings of subjective mental fatigue relate to cognitive performance in patients with myasthenia gravis. J Clin Neurosci 2002;9:243-6.
37. Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, Sanders DB. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Ann Thorac Surg 2000;70:327-34.
38. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
39. Al-Rajeh S, Ogunniyi A, Awada A, Daif A, Zaidan R. Preliminary assessment of an Arabic version of the Mini-Mental state examination. Ann Saudi Med 1999;19:150-2.
40. Delany EA, Hopkins TF. The Stanford. Binet Intelligence Scale: Examiner's Handbook. 4th ed. Chicago: The Riverside Publishing Co.; 1986.
41. Melika LK. The Stanford. Binet Intelligence Scale: Arabic Examiner's Handbook. 4th ed. Cairo: Dar El Maref Publishing; 1998.
44. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders 4th ed. Washington, DC: American Psychiatric Association; 1994. pp. 317-91.
45. Gharyb AG. Beck Depression Inventory-II (BDI-II), Arabic Examiner's Handbook. Cairo: Dar El-Anglo Publishing; 2000.
46. Beck AT, Steer RA, Ball R, Ranieri W. Comparison of beck depression inventories-IA and-II in psychiatric outpatients. J Pers Assess 1996;67:588-97.
47. Bartel PR, Lotz BP. Neuropsychological test performance and affect in myasthenia gravis. Acta Neurol Scand 1995;91:266-70.
48. Kirby AW, Wiley RW, Harding TH. Cholinergic effects on the visual evoked potential. In: Cracco RQ, Bodis-Wollner I, editors. Evoked Potentials. Alan R. Liss, New York; 1986. pp. 296–305.
49. Fotiou F, Papakostopoulos D, Hamlatzis P. Changes in the pattern reversal visual evoked potentials in myasthenia gravis. Electromyogr Clin Neurophysiol 1994;34:171-5.
50. Jech R, Ruzicka E. Brain stem auditory evoked potentials reflect central nervous system involvement in myasthenia gravis. J Neurol 1996;243:547-50.
51. Tzartos SJ, Sophianos D, Efthimiadis A. Role of the main immunogenic region of acetylcholine receptor in myasthenia gravis. An Fab monoclonal antibody protects against antigenic modulation by human sera. J Immunol 1985;134:2343-9.
52. Lindstrom J, Anand R, Peng X, Gerzanich V, Wang F, Li Y. Neuronal nicotinic receptor subtypes. In: Diversity of Interacting Receptors. Birkhäuser Basel; 1995. pp. 100–16.
53. Brejc K, van Dijk WJ, Klaassen RV, Schuurmans M, van Der Oost J, Smit AB, Sixma TK. Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors. Nature 2001;411:269-76.
54. Ji D, Lape R, Dani JA. Timing and location of nicotinic activity enhances or depresses hippocampal synaptic plasticity. Neuron 2001;31:131-41.
55. Darnell RB. Paraneoplastic neurologic disorders: windows into neuronal function and tumor immunity. Arch Neurol 2004;61:30-2.
56. Evoli A, Minicuci GM, Vitaliani R, Battaglia A, Della Marca G, Lauriola L, Fattorossi A. Paraneoplastic diseases associated with thymoma. J Neurol 2007;254:756-62.
57. Thorlacius S, Aarli JA, Riise T, Matre R, Johnsen HJ. Associated disorders in myasthenia gravis: autoimmune diseases and their relation to thymectomy. Acta Neurol Scand 1989;80:290-5.
59. Manfredi R, Fasulo G, Fulgaro C, Sabbatani S. Associated thyreoiditis, myasthenia gravis, thymectomy, Chron's disease, and erythema nodosum: pathogenetic and clinical correlations, immune system involvement, and systemic infectious complications. Rheumatol Int 2008;28:1173-5.
